GATT "substantial investment" would require ANDA acceptance prior to June 8, 1995 under Hatch amendment.
GATT "SUBSTANTIAL INVESTMENT" REQUIRES ANDA ACCEPTANCE PRIOR TO JUNE 8, 1995 under a replacing amendment by Sens. Hatch (R-Utah) and Specter (R-Penn.) during Judiciary Committee mark-up May 2 of legislation on marketing of generic drugs during the extended patent period under the General Agreement on Tariffs & Trade. The committee voted 10-7 to accept the Hatch/Specter amendment to replace the original bill offered by Sens. Pryor (D-Ark.), Brown (R-Colo.) and Chafee (R-R.I.).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth